NCT01563562: Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function |
|
|
| Completed | 1 | 34 | US | Bardoxolone Methyl | Reata, a wholly owned subsidiary of Biogen | Hepatic Impairment, Healthy | 11/12 | 11/12 | | |
